GLENMARK- ELOVERA , for dry skin disorders

New Drug Approvals

Compositions:
Elovera extract 10% cream, Vitamin E 0.5%

Category–Locally Acting Skin Preparations

Description

* Aqueeze adequate amount of elovera moisturizing body wash onto wet hands or wet loran and work into a creamy lather. apply it all ovr the body, keep for some time and then rinse with water.

http://www.drugneed.com/glenmark-pharmaceuticals-elovera-moisturizing-body-wash-150ml-glenmak-p-2017.html#tab4

Products Name : Elovera Moisturizing Body Wash 150ml – (Glenmark)

 

Elovera Cream, manufacture by Glenmark pharmaceuticals limited , is cream enriched with vitamin E and Aloe Vera. It’s a very special cream specially for treating scars and other minor pimple spots on the face.

reviews from net

My skin is very much oily hence I get these ugly Pimples very profoundly. On top of it i have the habit of bursting out the puss from these pimples. I always play it with my hands and as a result forms some very ugly scars on my face which are visible…

View original post 198 more words

Advertisements

Forigerimod, (Rigerimod) also known as Lupuzor, CEP-3345 for treatment of systemic lupus erythematosus (SLE)

New Drug Approvals

FORIGERIMOD

CHEMICAL NAMES
1. L-Tyrosine, L-arginyl-L-isoleucyl-L-histidyl-L-methionyl-L-valyl-L-tyrosyl-L-seryl-L-lysyl-L-arginyl-O-phosphono-L-serylglycyl-L-lysyl-L-prolyl-L-arginylglycyl-L-tyrosyl-L-alanyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-
2. O3,140-phosphono(human U1 small nuclear ribonucleoprotein 70 kDa (snRNP70))-(131-151)-peptide

MOLECULAR FORMULA C117H181N34O32PS
MOLECULAR WEIGHT 2639
TRADEMARK Lupuzor
SPONSOR Cephalon, Inc.
CODE DESIGNATION IPP 201101
CAS REGISTRY NUMBER 497156-60-2

STRUCTURAL FORMULA

stucture, http://www.ama-assn.org/ama1/pub/upload/mm/365/forigerimod.pdf

  1. Forigerimod nonproprietary drug name

    STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL. USAN. FORIGERIMOD.

    …………………………………………………………………………………………………………..

    FORIGERIMOD ACETATE

    CAS REGISTRY NUMBER 1160237-55-7  of acetate

    http://www.ama-assn.org/resources/doc/usan/forigerimod-acetate.pdf

     

  2. Forigerimod acetate nonproprietary drug name

    STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL. USAN. FORIGERIMOD ACETATE

    str is
    FORIGERIMOD ACETATE

Forigerimod, also known as Lupuzor or CEP-33457, (SyB L-1001) is a CD4 T-cell modulator being investigated for the treatment of systemic lupus erythematosus (SLE). In the Phase II trials, Lupuzor was administered subcutaneously at a dose of 200 mcg once a month for 3 months. The Phase III study is anticipated to…

View original post 534 more words

FDA accepts new drug application for investigational compound Epanova for the treatment of severe hypertriglyceridaemia

New Drug Approvals

LONDON, Sept. 18, 2013 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for EpanovaTM, an investigational compound for the treatment for patients with severe hypertriglyceridaemia (triglyceride levels greater than or equal to 500mg/dL). The NDA submission for Epanova was filed by Omthera Pharmaceuticals, now a wholly-owned subsidiary of AstraZeneca, as a 505(b)(1) application in July 2013. The Prescription Drug User Fee Act (PDUFA) goal date for the FDA is 5 May 2014.http://www.pharmalive.com/fda-accepts-astrazeneca-nda-for-epanova

View original post

FDA OKs Teva’s Injectable Treanda

New Drug Approvals

FDA OKs Teva’s Injectable Treanda

FDA Approves Teva’s Injectable Treanda

bendamustine

Sept. 17, 2013 (GLOBES)–Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced that the US Food and Drug Administration (FDA) has approved a new injectable version Treanda for treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and chronic lymphocytic leukemia. read all at

http://www.pharmalive.com/fda-oks-tevas-injectable-treanda

Bendamustine (INN, trade names TreakisymRibomustinLevact and Treanda; also known as SDX-105) is a nitrogen mustard used in the treatment of chronic lymphocytic leukemia[1] and lymphomas. It belongs to the family of drugs called alkylating agents. It is also being studied for the treatment of sarcoma.[2]

History

Bendamustine was first synthesized in 1963 by Ozegowski and Krebs in East Germany(the former German Democratic Republic). Until 1990 it…

View original post 2,964 more words

US FDA grants breakthrough therapy designation to Boehringer Ingelheim’s volasertib to treat patients with AML

New Drug Approvals

Volasertib

755038-65-4

CHEMICAL NAMES
1. Benzamide, N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-
ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-
methoxy-
2. N-{trans-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-4-{[(7R)-7-ethyl-5-methyl-8-
(1-methylethyl)-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxybenzamide

CODE DESIGNATION BI 6727

Ingelheim, Germany
Thursday, September 19, 2013, 16:00 Hrs  [IST]

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Boehringer Ingelheim’s  volasertib, a selective and potent polo-like kinase (Plk) inhibitor, for the treatment of patients with acute myeloid leukaemia (AML), a type of blood cancer.

http://www.pharmabiz.com/NewsDetails.aspx?aid=77733&sid=2

Volasertib (also known as BI 6727) is a small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed byBoehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives.[1]

Mechanism of action

Volasertib is a novel small-molecule targeted therapy that blocks cell division by competitively binding to the ATP-binding pocket of the PLK1 protein. PLK1 proteins are found in the nuclei of all dividing cells and control multiple stages of…

View original post 2,214 more words

Mogamulizumab

New Drug Approvals

 

Immunoglobulin G1, anti-(CC chemokine receptor CCR4) (human-mouse monoclonal
KW-0761 heavy chain), disulfide with human-mouse monoclonal KW-0761 κ-chain,
dimer

Immunoglobulin G1, anti-(human C-C chemokine receptor type 4 (CCR4, K5-5,
CD194)); humanized mouse monoclonal KW-0761 γ1 heavy chain (222-219′)-disulfide
with humanized mouse monoclonal KW-0761 κ light chain, dimer (228-228”:231-231”)-
bisdisulfide
MOLECULAR FORMULA C6520H10072N1736O2020S42 (peptide)
MOLECULAR WEIGHT 146.44 kDa (peptide)

SPONSOR Kyowa Hakko Kirin Co., Ltd.
CODE DESIGNATION KW-0761, KM8761
CAS REGISTRY NUMBER 1159266-37-1

THERAPEUTIC CLAIM Antineoplastic

http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf  for structure

Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4(CCR4). It has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.[1]

Mogamulizumab was developed by Kyowa Hakko Kirin Co., Ltd.[2]

T-cell neoplasms, such as adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma, are particularly aggressive and, despite novel combination chemotherapy regimens, still have extremely…

View original post 1,396 more words